Promoter Hypermethylation in White Blood Cell DNA and Breast Cancer Risk

The role of gene-specific methylation in white blood cells (WBC) as a marker of breast cancer risk is currently unclear. We determined whether promoter hypermethylation in blood DNA of candidate tumor suppressor genes frequently methylated in breast tumors can be used as a surrogate biomarker for breast cancer risk. Promoter methylation of BRCA1, CDH1 and RARβ was analyzed in WBC DNA from a population-based sample of 1,021 breast cancer patients and 1,036 controls by the MethyLight assay. Gene-specific promoter methylation in the DNA of 569 tumor tissue samples was also analyzed to determine the correlation of methylation levels with blood from the same individual. Hypermethylation of BRCA1 (OR: 1.31; 95% CI: 0.98-1.75) in WBC was associated with an increased risk of breast cancer when positive methylation was defined as ≥0.1% methylated. There was lack of concordance between tumor tissue and paired WBC DNA methylation. These results provide limited support that hypermethylation of BRCA1 in WBC DNA may be useful for determination of breast cancer risk. Additional studies with larger numbers of genes are needed to fully understand the relationship between WBC methylation and breast cancer risk.

[1]  M. Widschwendter,et al.  DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. , 2004, Clinical chemistry.

[2]  H. Toutenburg.  Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S. , 1974 .

[3]  M. Widschwendter,et al.  DNA methylation in serum of breast cancer patients: an independent prognostic marker. , 2003, Cancer research.

[4]  Anurag Srivastava,et al.  Clinical Significance of Promoter Hypermethylation of ERβ and RARβ2 in Tumor and Serum DNA in Indian Breast Cancer Patients , 2012, Annals of Surgical Oncology.

[5]  A. Neugut,et al.  Weight Gain Prior to Diagnosis and Survival from Breast Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[6]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[7]  H. Brenner,et al.  Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study , 2008, PloS one.

[8]  Maurice B Loughrey,et al.  BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype , 2008, Breast Cancer Research.

[9]  Mary Beth Terry,et al.  The Long Island Breast Cancer Study Project: Description of a Multi-Institutional Collaboration to Identify Environmental Risk Factors for Breast Cancer , 2002, Breast Cancer Research and Treatment.

[10]  P. Laird,et al.  Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. , 2000, Cancer research.

[11]  Xiaotu Ma,et al.  Identification of Breast Cancer DNA Methylation Markers Optimized for Fine-Needle Aspiration Samples , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[12]  Graham G. Giles,et al.  Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer , 2010, Cancer Prevention Research.

[13]  Jose M. Silva,et al.  Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. , 1999, Cancer research.

[14]  A. Neugut,et al.  Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients , 2011, Breast Cancer Research and Treatment.

[15]  An-Qin Zhang,et al.  Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels. , 2012, International journal of oncology.

[16]  D. Wooff.  Logistic Regression: a Self-learning Text, 2nd edn , 2004 .

[17]  A. Neugut,et al.  Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  Matthias Schroder,et al.  Logistic Regression: A Self-Learning Text , 2003 .

[19]  W. Conover.  Statistical Methods for Rates and Proportions , 1974 .

[20]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[21]  Martin Widschwendter,et al.  Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.

[22]  A. Neugut,et al.  BRCA1 promoter methylation is associated with increased mortality among women with breast cancer , 2009, Breast Cancer Research and Treatment.

[23]  S Greenland,et al.  Modeling and variable selection in epidemiologic analysis. , 1989, American journal of public health.

[24]  P. Laird,et al.  Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version , 2001 .

[25]  J. Peto,et al.  Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients , 2009, Human molecular genetics.

[26]  T. Taguchi,et al.  BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation , 2011, Breast Cancer Research and Treatment.

[27]  B. Everitt,et al.  Statistical methods for rates and proportions , 1973 .

[28]  R. Pili,et al.  Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. , 2002, Cancer research.

[29]  J. Herman,et al.  Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. , 2000, Cancer research.

[30]  L. Hansen,et al.  Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events , 2011, Diagnostic pathology.

[31]  L. Hansen,et al.  No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls. , 2011, Future oncology.

[32]  Y. Bignon,et al.  BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. , 2012, Cancer epidemiology.

[33]  P. Korkolopoulou,et al.  Association of aberrant DNA methylation with clinicopathological features in breast cancer. , 2011, Oncology reports.

[34]  Pedram Argani,et al.  Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer , 2004, Cancer Research.

[35]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[36]  Michael Jones,et al.  Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. , 2012, Cancer research.

[37]  P. Toniolo,et al.  Methylation signature of lymph node metastases in breast cancer patients , 2012, BMC Cancer.